Cost-utility of universal hepatitis A vaccination in Canada.
作者： CT Bauch , AM Anonychuk , BZ Pham , V Gilca , B Duval
DOI: 10.1016/J.VACCINE.2007.10.001
关键词:
摘要: Hepatitis A (HA) vaccination in Canada is currently targeted toward high-risk groups. The cost-effectiveness and expected health outcomes of universal relative to low-incidence countries such as are unknown. Here, we conducted a cost-utility analysis for this situation, with the study population. We included vaccine costs, time infection public costs. assessed range possible strategies over an 80-year horizon using multiple cost perspectives. dynamic model was used account herd immunity. Aggregate gains from switching modest (10-30 QALYs per year). However, "9+9" strategy that replaces two doses monovalent hepatitis B (HB) at 9/10 years (universally administered most provinces) bivalent HA/HB cost-saving societal perspective. At willingness pay threshold $50,000/QALY, mean net benefit +49.4 (S.D. 12.6) perspective +3.8 QALYS 3.0) payer strategy. Net sensitive marginal HB vaccine. Similar conclusions may apply other low incidence policy.
elsevier.com
sci-hub.se 参考文章(41)
Susie ElSaadany, Paul Gully, Antonio Giulivi, Hepatitis A, B, and C in Canada. Results from the National Sentinel Health Unit Surveillance System, 1993-1995. Canadian Journal of Public Health-revue Canadienne De Sante Publique. ,vol. 93, pp. 435- 438 ,(2002) , 10.1007/BF03405032
M Guay, P Wals De, C Roy, M Blackburn, J Desrochers, AM Clouâtre, G Baron, F Milord, Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren Canadian Journal of Public Health-revue Canadienne De Sante Publique. ,vol. 94, pp. 64- 67 ,(2003) , 10.17269/CJPH.94.367
Ba' Pham, Bernard Duval, Gaston De Serres, Vladimir Gilca, Andrea C Tricco, Jan Ochnio, David W Scheifele, Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review. BMC Infectious Diseases. ,vol. 5, pp. 56- 56 ,(2005) , 10.1186/1471-2334-5-56
Arni SR Srinivasa Rao, Maggie H Chen, Ba' Z Pham, Andrea C Tricco, Vladimir Gilca, Bernard Duval, Murray D Krahn, Chris T Bauch, Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A BMC Infectious Diseases. ,vol. 6, pp. 174- 174 ,(2006) , 10.1186/1471-2334-6-174
Allen S. Craig, William Schaffner, Prevention of Hepatitis A with the Hepatitis A Vaccine New England Journal of Medicine. ,vol. 350, pp. 476- 481 ,(2004) , 10.1056/NEJMCP031540
Isabelle Rouleau, Bernard Duval, Ramak Shadmani, Monika Naus, Brian J. Ward, Cathy Gosselin, Gaston De Serres, Comparison of trip characteristics of children and adults with travel-acquired hepatitis A infection. Pediatric Infectious Disease Journal. ,vol. 25, pp. 1184- 1186 ,(2006) , 10.1097/01.INF.0000246852.21859.92
Loriana Di Giammarino, Jules L. Dienstag, Hepatitis A--the price of progress. The New England Journal of Medicine. ,vol. 353, pp. 944- 946 ,(2005) , 10.1056/NEJME058152
Taraz Samandari, Beth P. Bell, Gregory L. Armstrong, Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine. ,vol. 22, pp. 4342- 4350 ,(2004) , 10.1016/J.VACCINE.2004.04.014
R. Jake Jacobs, Gene A. Gibson, Allen S. Meyerhoff, Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. Infection Control and Hospital Epidemiology. ,vol. 25, pp. 563- 569 ,(2004) , 10.1086/502440
Bernard Duval, Vladimir Gîlca, Nicole Boulianne, Genevieve Deceuninck, Louis Rochette, Gaston De Serres, Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine. ,vol. 23, pp. 4082- 4087 ,(2005) , 10.1016/J.VACCINE.2004.07.022